Figure 5. Adoptive transfer of Fas DNR–modified T cells enhances antitumor efficacy independently of T cell differentiation status.

(A) Representative FACS plots demonstrating the purity of sorted CD62L⁺CD44⁺Thy1.1⁺ T_CM-like pmel-1 T cells modified with Fas^ΔDD or empty vector control prior to infusion. The percentage of gated Thy1.1⁺CD62L⁺ cells is shown in the FACS plot. (B) Tumor regression and (C) survival of mice bearing 10-day-established B16 melanoma tumors that were untreated or received 5 × 10⁵ of sort-purified T_CM-like Thy1.1⁺ modified cells. Representative results from 2 independent experiments are shown as mean ± SEM using n = 5–8 mice/cohort. Statistical comparisons were performed using Wilcoxon’s rank-sum test (B) or log-rank Mantel-Cox test (C); *P < 0.05.